A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

Inclusion Criteria: * Are Overtly healthy males or nonpregnant females of childbearing or non-childbearing potential as determined through medical evaluation. * Agree not to donate blood or plasma until after the end of their participation in the study * Have a body mass index (BMI) within the range 18.0 to 32.0 kilograms per meter squared (kg/m²) Exclusion Criteria: * Are females who are pregnant or lactating. * Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs * Have a history or presence of psychiatric disorders * Show evidence of human immunodeficiency virus infection. * Show evidence of hepatitis C and/or hepatitis B * Medical history of allergic reaction to humanized monoclonal antibodies * Have had lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years. * Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study. * Smoke more than 10 cigarettes per day or the equivalent including electronic cigarettes or are unable to abide by CRU smoking restrictions